Please assess the completion status of the following clinical trial:

Trial Title: Preventing pAIn With NMDA Antagonists - Steroids in Thoracoscopic lObectomy Procedures (PAIN-STOP) Pilot Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 18-75 years of age,~* Planned elective VATS pulmonary lobectomy,~* Provide written informed consent to participate.~Exclusion Criteria:~* Current pain on the same side of the chest of moderate to severe intensity (\>3/10 in 0-10 numerical rating scale (NRS) - where 0=no pain, 10=maximum pain),~* Known intracranial mass or cerebral aneurysm or raised intraocular pressure,~* Severe renal impairment (creatinine clearance based GFR of \<30ml/min),~* Allergies to one or more of the study medications,~* Steroid treatment \> 10mg/day of Prednisolone or its equivalent for \> 3 weeks within the last 3 months,~* History of schizophrenia or bipolar disorder,~* History of drug addiction (prescription or non-prescription drug addiction diagnosed by a physician, excluding alcohol),~* Current diagnosis of Cushing's syndrome,~* Pregnancy,~* Previous participation in the PAIN-STOP trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- NMDA active + Steroid placebo (Type: EXPERIMENTAL): NMDA active: ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID \[first week\]; 10 mg BID \[following three weeks\]).~Steroid placebo: two doses of normal saline; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day.
- Steroid active + NMDA placebo (Type: EXPERIMENTAL): NMDA placebo: normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (one capsule BID \[first week\]; one capsule BID \[following three weeks\]).~Steroid active: two doses of dexamethasone; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day.
- NMDA active + Steroid active (Type: EXPERIMENTAL): NMDA active: ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID \[first week\]; 10 mg BID \[following three weeks\]).~Steroid active: two doses of dexamethasone; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day.
- NMDA placebo + Steroid placebo (Type: PLACEBO_COMPARATOR): NMDA placebo: normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (one capsule BID \[first week\]; one capsule BID \[following three weeks\]).~Steroid placebo: two doses of normal saline; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues